Statistical Analysis
We determined that a total of 3452 patients would provide 80% power to detect a 45% rate of patients with mRS scores of 0 or 1 on day 90 after randomization in the placebo groupAll the analyses were performed in the modified intention-to-treat population, which comprised all the patients who had undergone randomization and had at least 1 assessment of efficacy after baseline. Baseline data were presented according to treatment assignment. Continuous variables were presented as mean (SD) or median (IQR) according to the distribution, and categorical variables were presented as frequency and proportion. The differences in the proportions for the dichotomous outcomes between treatment groups and their corresponding 95% CIs were estimated based on the Newcombe-Wilson score method.